Core Viewpoint - North Chip Life (688712.SH) reported a significant increase in revenue and profitability for the fiscal year 2025, indicating strong operational performance and effective management strategies [1][2]. Financial Performance - The company achieved an operating revenue of 542 million yuan, representing a year-on-year growth of 71.23% [1]. - The net profit attributable to the parent company was 80.62 million yuan, with a net profit of 65.14 million yuan after deducting non-recurring gains and losses, marking a turnaround from losses in the previous year [1]. Business Growth Factors - The core products of the company have gained widespread recognition from domestic and international experts due to their significant clinical value and differentiated innovation, addressing unmet clinical needs [2]. - The company's products are now utilized in over 60 countries and regions, with clinical applications in more than 2,000 hospitals [2]. - Overseas business revenue grew by over 130% year-on-year, contributing to an increased share of international business in total revenue [2]. Research and Development - The company continues to invest in research and development, particularly in the fields of intelligent and precise interventional treatment, focusing on foundational design and technological innovation [2]. - The pipeline for precision diagnosis and treatment of cardiovascular diseases is steadily advancing, providing new momentum for sustainable long-term development [2]. Operational Efficiency - The company is enhancing its organizational and operational capabilities while continuously improving its governance structure [2]. - As the scale of main business revenue expands rapidly, the company has effectively controlled its expense ratio during the reporting period [2].
北芯生命(688712.SH)业绩快报：2025年归母净利润8062.19万元